Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577212 | 0.87 | MEN1 (0.50) | MEN1KMT2ARAB9AALDH1A1POLB | |
| SCHEMBL5799865 | 0.84 | MEN1 (0.46) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL5577291 | 0.79 | TACR1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5577564 | 0.75 | SMN1; SMN2 (0.40) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2234342 | 0.72 | PTPRB (0.52) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL9543049 | 0.71 | MEN1 (0.43) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL22338893 | 0.71 | KMT2A (0.52) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL6823644 | 0.71 | KMT2A (0.49) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL5019060 | 0.71 | KMT2A (0.52) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL18307298 | 0.71 | KMT2A (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142467-A1 | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission | THE UNIVERSITY OF MONTANA (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2006047251-A2 | 3-ALKYLARYL ASPARTATE COMPOUNDS AND THEIR USE FOR SELECTIVE ENHANCEMENT OF SYNAPTIC TRANSMISSION | THE UNIVERSITY OF MONTANA (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142467-A1 | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission | SLC1A1, SLC1A3, SLC1A2 | MEN1 4165/4885KMT2A 1036/4885NPC1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.